PharmTech Drug Digest 11.20
|Articles|August 12, 2016

Road to Global Serialization

With the increase in the drug counterfeiting across the world, many countries along with the Global Standards body (GS1) have come up with various country regulations which can keep counterfeiting at bay. With Serialization and new traceability requirements in many countries, the life sciences industry is undergoing a paradigm shift in the way it labels and transacts sales of prescription drugs and biologic products.

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.